Cargando…

Differential Effects of 1α,25-Dihydroxyvitamin D(3) on the Expressions and Functions of Hepatic CYP and UGT Enzymes and Its Pharmacokinetic Consequences In Vivo

The compound 1α,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is the active form of vitamin D(3) and a representative ligand of the vitamin D receptor (VDR). Previous studies have described the impacts of 1,25(OH)(2)D(3) on a small number of cytochrome P450 (CYP) and uridine diphosphate-glucuronyltrans...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doan, Trang Nguyen Kieu, Vo, Dang-Khoa, Kim, Hyojung, Balla, Anusha, Lee, Yunjong, Yoon, In-Soo, Maeng, Han-Joo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700423/ https://www.ncbi.nlm.nih.gov/pubmed/33238436 http://dx.doi.org/10.3390/pharmaceutics12111129

Ejemplares similares

Effects of 1α,25-dihydroxyvitamin D(3) on the pharmacokinetics and biodistribution of ergothioneine, an endogenous organic cation/carnitine transporter 1 substrate, in rats
por: Vo, Dang-Khoa, et al.
Publicado: (2022)

Effects of 1α,25-Dihydroxyvitamin D(3) on the Pharmacokinetics of Procainamide and Its Metabolite N-Acetylprocainamide, Organic Cation Transporter Substrates, in Rats with PBPK Modeling Approach
por: Balla, Anusha, et al.
Publicado: (2021)

Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine
por: Calleja, Sofía, et al.
Publicado: (2023)

The reference liver—CYP450 and UGT enzymes in healthy donor and metastatic livers: the impact of genotype
por: Kurzawski, Mateusz, et al.
Publicado: (2021)

The Effect of UGT1A9, CYP2B6 and CYP2C9 Genes Polymorphism on Propofol Pharmacokinetics in Children
por: Pavlovic, Dimitrije, et al.
Publicado: (2020)

Primary Human Osteoblasts in Response to 25-Hydroxyvitamin D(3), 1,25-Dihydroxyvitamin D(3) and 24R,25-Dihydroxyvitamin D(3)
por: van der Meijden, Karen, et al.
Publicado: (2014)

Epigenetic regulation of the 1,25-dihydroxyvitamin D(3) 24-hydroxylase (CYP24A1) in colon cancer cells
por: Höbaus, Julia, et al.
Publicado: (2013)

THU397 Homeostatic Regulation Of 1,25-dihydroxyvitamin D: Critical Role Of 24-hydroxylation (CYP24A1)
por: Yazdi, Zhinoosossadat Shahidzadeh, et al.
Publicado: (2023)

Development and Validation of a Bioanalytical LC-MS/MS Method for Simultaneous Determination of Sirolimus in Porcine Whole Blood and Lung Tissue and Pharmacokinetic Application with Coronary Stents
por: Nguyen, Thi-Thao-Linh, et al.
Publicado: (2021)

Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients
por: Areepium, N, et al.
Publicado: (2013)

Characterization of CYPs and UGTs Involved in Human Liver Microsomal Metabolism of Osthenol
por: Cho, Pil Joung, et al.
Publicado: (2018)

THU233 Reduction Of Overutilization Of 1,25-Dihydroxyvitamin D
por: Brown, Jeremy, et al.
Publicado: (2023)

Simultaneous Determination of Procainamide and N-acetylprocainamide in Rat Plasma by Ultra-High-Pressure Liquid Chromatography Coupled with a Diode Array Detector and Its Application to a Pharmacokinetic Study in Rats
por: Balla, Anusha, et al.
Publicado: (2018)

Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria
por: Palikhe, Nami Shrestha, et al.
Publicado: (2011)

Serum 1,25-Dihydroxyvitamin D: An Outcome Prognosticator in Human Sepsis
por: Nguyen, H. Bryant, et al.
Publicado: (2013)

Expression of nephronectin is enhanced by 1α,25‐dihydroxyvitamin D(3)
por: Hiranuma, Katsuhiro, et al.
Publicado: (2016)

Focus on 1,25-Dihydroxyvitamin D3 in the Peripheral Nervous System
por: Faye, Pierre Antoine, et al.
Publicado: (2019)

The Use of 1α,25-Dihydroxyvitamin D(3) as an Anticancer Agent
por: Marcinkowska, Ewa, et al.
Publicado: (2016)

No major effects of vitamin D(3) (1,25 dihydroxyvitamin D(3)) on absorption and pharmacokinetics of folic acid and fexofenadine in healthy volunteers
por: Kullak-Ublick, Gerd A., et al.
Publicado: (2016)

Physiologically-Based Pharmacokinetic Modeling for Drug-Drug Interactions of Procainamide and N-Acetylprocainamide with Cimetidine, an Inhibitor of rOCT2 and rMATE1, in Rats
por: Jeong, Yoo-Seong, et al.
Publicado: (2019)

Complete Reaction Phenotyping of Propranolol and 4-Hydroxypropranolol with the 19 Enzymes of the Human UGT1 and UGT2 Families
por: Yang, Fan, et al.
Publicado: (2022)

Association of increased renal Cyp24a1 gene expression with low plasma 1,25-dihydroxyvitamin D levels in rats with streptozotocin-induced diabetes
por: Tajiri, Mari, et al.
Publicado: (2020)

The effect of UGT1A9, CYP2B6 and CYP2C9 genes polymorphism on individual differences in propofol pharmacokinetics among Polish patients undergoing general anaesthesia
por: Mikstacki, Adam, et al.
Publicado: (2016)

Brain Endothelial P-Glycoprotein Level Is Reduced in Parkinson’s Disease via a Vitamin D Receptor-Dependent Pathway
por: Kim, Hyojung, et al.
Publicado: (2020)

Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients
por: So, W. Venus, et al.
Publicado: (2018)

Physiologically‐Based Pharmacokinetic Modeling of the Drug–Drug Interaction of the UGT Substrate Ertugliflozin Following Co‐Administration with the UGT Inhibitor Mefenamic Acid
por: Callegari, Ernesto, et al.
Publicado: (2020)

25-Hydroxyvitamin D, 1,25-Dihydroxyvitamin D, and Peripheral Bone Densitometry in Adults with Celiac Disease
por: Ciacci, Carolina, et al.
Publicado: (2020)

Characteristics of Serum Ratios of 1,25-Dihydroxyvitamin D to 25-Hydroxyvitamin D for Assessment of Bone Metabolism
por: Yamamoto, Koichiro, et al.
Publicado: (2021)

Attenuation of constitutive DNA damage signaling by 1,25-dihydroxyvitamin D3
por: Halicka, H. Dorota, et al.
Publicado: (2012)

The relationship of 1,25-dihydroxyvitamin D and Vitamin D binding protein in periodontitis
por: Rafique, Sara, et al.
Publicado: (2019)

Mechanistic study of the cause of decreased blood 1,25-Dihydroxyvitamin D in sepsis
por: Li, Chih-Huang, et al.
Publicado: (2019)

Effects of anemoside B4 on pharmacokinetics of florfenicol and mRNA expression of CXR, MDR1, CYP3A37 and UGT1E in broilers
por: LI, Sicong, et al.
Publicado: (2019)

The role of sex, age and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs
por: Trenaman, Shanna C., et al.
Publicado: (2021)

Effects of ABCB1, UGT1A1, and UGT1A9 Genetic Polymorphisms on the Pharmacokinetics of Sitafloxacin Granules in Healthy Subjects
por: Sun, Lu‐Ning, et al.
Publicado: (2020)

8-Cl-Adenosine enhances 1,25-dihydroxyvitamin D(3)-induced growth inhibition without affecting 1,25-dihydroxyvitamin D(3)-stimulated differentiation of primary mouse epidermal keratinocytes
por: Bollag, Wendy B, et al.
Publicado: (2004)

Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation
por: Dusso, Adriana S
Publicado: (2011)

25-Hydroxyvitamin D(3) and 1,25-Dihydroxyvitamin D(3) Promote the Differentiation of Human Subcutaneous Preadipocytes
por: Nimitphong, Hataikarn, et al.
Publicado: (2012)

MON-374 Management of 1,25-dihydroxyvitamin D (1,25-OHD) Mediated Hypercalcemia of Unknown Etiology
por: Menon, Sruthi, et al.
Publicado: (2020)

Differential Metabolic Stability of 4α,25- and 4β,25-Dihydroxyvitamin D(3) and Identification of Their Metabolites
por: Mizumoto, Yuka, et al.
Publicado: (2023)

Rhododendrin-Induced RNF146 Expression via Estrogen Receptor β Activation is Cytoprotective Against 6-OHDA-Induced Oxidative Stress
por: Kim, Hyojung, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bha45ib067ht6p8ntui8r9m12m